Spotlight: (Original article published in Journal of Hematology & Oncology https://t.co/JYk5HVUhTi) #Tcell #CAR #clinicaltrial https://t.co/826CqSkJnn
A Phase I, Open-Label Study of LCAR-B38M, a Chimeric Antigen Receptor T Cell Therapy Directed against B Cell Maturation Antigen, in Patients with Relapsed or Refractory Multiple Myeloma https://t.co/ofn5cRl2MZ
This was presented at ASCO and ASH, data finally published!!! A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma https:
RT @Myeloma_Doc: Phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against BCMA, shows impressive…
RT @Myeloma_Doc: Phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against BCMA, shows impressive…
RT @Myeloma_Doc: Phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against BCMA, shows impressive…
RT @Myeloma_Doc: Phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against BCMA, shows impressive…
Phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against BCMA, shows impressive activity in patients with relapsed or refractory multiple #myeloma: https://t.co/dljOox9C4n. https://t.co/j1wi563R3K
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma https://t.co/0Y74Yiw68f #
LCAR-B38M CAR T cell therapy displayed a manageable safety profile and demonstrated deep and durable responses in patients with R/R MM. https://t.co/e5eOocguWx #Tcell #MM
RT @sesiegler: A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation anti…
RT @sesiegler: A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation anti…
RT @sesiegler: A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation anti…
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma | Journal of Hematology & Oncology | Full Text https://t.co/UXQPqQ
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma #CARTCells https://t.co/Ko53saZpGa